Navigation Links
Two New Imaging Studies Show Higher Dose Lipitor Stopped the,Progression of Atherosclerosis

NEW ORLEANS--(BUSINESS WIRE)--Mar 26, 2007 - Pfizer said today that results from two new imaging trials showed that higher dose Lipitor stopped the progression of atherosclerosis in patients with coronary heart disease or familial hypercholesterolemia (FH). The trials, which were designed to investigate the efficacy of the former investigational compound torcetrapib in combination with Lipitor compared to Lipitor alone, were presented today at the annual meeting of the American College of Cardiology.

In the Lipitor arm of the ILLUSTRATE and RADIANCE 1 trials, patients took an average Lipitor dose of 23 mg and 56 mg respectively and experienced halting of the progression of atherosclerosis. In the ILLUSTRATE trial, treatment with Lipitor resulted in plaque regression in the most diseased part of the coronary artery. In contrast in the Lipitor arm of RADIANCE 2 patients took a low average Lipitor dose of 13 mg and progression of atherosclerosis was observed.

"From a clinical perspective, what is remarkable in these studies is that Lipitor was able to stop the progression of disease, including the most difficult to treat FH patients studied in RADIANCE 1," said Professor John Kastelein, lead investigator for two of the trials, and professor of medicine and chairman of vascular medicine at the Academic Medical Center in Amsterdam. "These trials build on the effects seen with Lipitor in numerous imaging trials."

Lipitor is the only statin to have been studied in head-to-head imaging trials. In the ASAP and ARBITER trials, which measured changes in cIMT, high-risk patients who took Lipitor 80 mg experienced regression in atherosclerosis compared with patients who took other statins. In the REVERSAL trial, Lipitor patients experienced a halting of plaque progression compared with pravastatin, and Lipitor patients experienced a significant reduction in the plaque volume in the most diseased segments compa
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
2. Repligen Reports Positive Phase 2 Clinical Trial Results of Secretin for MRI Imaging of the Pancreas
3. Avid Announces Results of AV-1 Molecular Imaging Agent for Alzheimers Disease Presented at AD/PD Meeting
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
6. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
7. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
8. Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
9. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
10. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
11. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
Post Your Comments:
(Date:9/18/2014)... , Sept. 18, 2014  Zacks.com announces the ... day the Zacks Equity Research analysts discuss the latest ... Stocks recently featured in the blog include the Avanir Pharmaceuticals ... (Nasdaq: NPSP - Free Report ), Orexigen (Nasdaq: ... MDVN - Free Report ) and Gilead (Nasdaq: ...
(Date:9/18/2014)... Australia , Sept. 18, 2014 Veterinary ... of Dr. Ashraf Hanna , M.D., Ph.D., and ... Board of Directors. Dr. Hanna is the Vice President ... Chief Financial Officer for the Genentech Foundation, while Dr. ... Head of Business Development and Licensing for Roche Pharma. ...
(Date:9/18/2014)... , Sept. 18, 2014   Regulus Therapeutics ... biopharmaceutical company leading the discovery and development of ... initiated its ATHENA natural history of disease study ... kidney disease with no approved therapy. The ATHENA ... of renal function markers such as Glomerular Filtration ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 4The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 5The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 6Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6
... , BOCA RATON, Fla., Nov. 16 CPG has ... Management (PLM) Release 9.3 at Avema Pharma Solutions, a division ... operation of pharmaceutical, over-the-counter (OTC), and nutritional solid-dose products based ... live at Avema on September 28, 2009. "As a contract ...
... , JAMAICA PLAIN, Mass., Nov. 16 ... presentation today at the AACR-NCI-EORTC International Conference Molecular Targets ... efficiently penetrates the blood brain barrier and may be ... Olaf van Tellingen, Ph.D. of The Netherlands Cancer Institute, ...
Cached Medicine Technology:CPG Implements First-Ever Agile PLM Release 9.3 at Avema Pharma Solutions 2Paloma Pharmaceuticals Presents at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics 2Paloma Pharmaceuticals Presents at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics 3
(Date:9/18/2014)... drink less sugar, according to a new study from ... enough, the study goes on to say, as all ... healthier at school , The research suggests a parent,s ... a child,s diet. , The study found Vancouver school ... per cent more likely to eat vegetables during the ...
(Date:9/18/2014)... 18, 2014 Relias Learning, the leader in ... services markets, today announced it has been named to the ... companies in America. , In the three-year period from 2010 ... almost 2,000 spots on the Inc. 5000 list to 1,025 ... , “The industries we serve continue to grow, and the ...
(Date:9/18/2014)... Gables, FL (PRWEB) September 18, 2014 ... a portion of proceeds to Feeding America Eastern Wisconsin. ... Days, 7 Ways to Save” with Turbana bananas and ... be two for $4 and Turbana bananas will be ... $1 for every two Fyffes pineapples that are purchased ...
(Date:9/18/2014)... T-System Inc. today announced Holyoke Medical Center ... EV™ for physicians — improving productivity ... solutions, Holyoke chose T-System’s solution because not only ... reimbursement, but also its ability to integrate with ... to capture emergency department, (ED) nurse documentation. , ...
(Date:9/18/2014)... Fit Body Boot Camp , an ... in the country and its popularity, as both a franchise ... enormously in 2014. , The company’s annual business conference, ... in Costa Mesa, CA on September 26 and 27, and ... Founder Bedros Keuilian, who is also considered the leading fitness ...
Breaking Medicine News(10 mins):Health News:Kids eat better if their parents went to college 2Health News:Relias Learning Named to Inc. 5000 List for Second Consecutive Year 2Health News:Turbana Partners with Sendik's Food Market to Donate Portion of Proceeds to Local Hunger-Relief Non-Profit 2Health News:Turbana Partners with Sendik's Food Market to Donate Portion of Proceeds to Local Hunger-Relief Non-Profit 3Health News:Holyoke Medical Center ER Improves Productivity and Reimbursement with T-System 2Health News:With Fit Body Boot Camp World Conference Nearing, Founder Explains the Fitness Boot Camp Franchise’s Success 2Health News:With Fit Body Boot Camp World Conference Nearing, Founder Explains the Fitness Boot Camp Franchise’s Success 3
... arteries remains the leading cause of disease and death in ... Medicine researcher is helping to open new pathways toward treating ... of biomedical sciences, is researching mutant forms of a human ... grow new blood vessels to restore blood flow in damaged ...
... Source Endurance is pleased to,announce that it ... Sports and,Fitness of San Marcos Texas to collaborate ... encompass several areas of,collaboration including the sharing and ... training approaches, and deployment of one,of the first ...
... Children,s Research Hospital have demonstrated that children with ... can retain normal function in both kidneys by ... when preoperative scans suggest that the tumors are ... St. Jude patients with bilateral Wilms tumor exhibiting ...
... Programs to be Marketed to Over 50,000 Members ... ... CANTEL MEDICAL,CORP. (NYSE: CMN ) and the National Safety Council ... prepare for the threat of a flu pandemic and similar,infectious diseases. The ...
... A SpaCapsule, Could Change The Outcome Of This ... Year,s Presidential Election, MIAMI, March 24 ... John McCain, Hillary Clinton and,Barack Obama,s stress levels are at an all ... city to city making,numerous public appearances. This can cause lack of sleep ...
... A study by a New York University dental research ... (gum) disease are more likely to develop gestational diabetes ... , The study, led by Dr. Ananda P. Dasanayake, ... NYU College of Dentistry, followed 256 women at New ...
Cached Medicine News:Health News:FSU researcher's 'mutant' proteins could lead to new treatment for heart disease 2Health News:Source Endurance and So High Sports Announce Research Alliance for Physiology and Human Performance 2Health News:Source Endurance and So High Sports Announce Research Alliance for Physiology and Human Performance 3Health News:St. Jude study offers new hope for children with kidney tumors deemed inoperable 2Health News:Cantel Medical Corp. and National Safety Council Launch Joint Initiative to Prepare Businesses and Individuals for Flu Pandemic 2Health News:Cantel Medical Corp. and National Safety Council Launch Joint Initiative to Prepare Businesses and Individuals for Flu Pandemic 3Health News:Stress On The Campaign Trail, One Issue All The Candidates Agree On 2Health News:NYU dental researchers find evidence of periodontal disease leading to gestational diabetes 2
Titanium. Straight shafts with 6 mm platform and Pierse tips. Flat serrated handle with dull finish....
Delicate strong curved serrated tips. Serrated handle with dull finish....
1 x 2 teeth, cross serrated 5 mm 60 degree angled platform. Round knurled handle with polished finish....
Two 2.75 mm long tips separated 1 mm with 1 x 2 teeth. Serrated handle with dull finish....
Medicine Products: